A Window Trial of 5-Azacytidine or Nivolumab or Combination Nivolumab Plus 5-Azacytidine in Resectable HPV-Associated Head and Neck Squamous Cell Cancer
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Nivolumab (Primary) ; Lorazepam; Prochlorperazine
- Indications Carcinoma; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 Apr 2023 Status changed from not yet recruiting to recruiting.
- 09 Mar 2023 Planned initiation date changed from 1 Feb 2023 to 1 Mar 2023.
- 07 Feb 2023 Planned initiation date changed from 1 Jan 2023 to 1 Feb 2023.